I spent the weekend with thousands of blood disease researchers. This is what happened.
Juno now finds itself one year, if not two years or more, behind rivals Novartis and Kite.
While a phase III study progresses, Acceleron is searching for different populations of MDS patients where luspatercept might also be effective.
A nanotechnology derived artificial red blood cell could be used in life-saving situations like trauma accidents or the battlefield where donated blood is unavailable.